Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3417
-0.0593-14.79%
Volume:620.10K
Turnover:226.16K
Market Cap:12.90M
PE:-0.78
High:0.3850
Open:0.3800
Low:0.3375
Close:0.4010
52wk High:1.33
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.58
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-8.27
PE(LYR):-0.78

Loading ...

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

TIPRANKS
·
Jul 02

Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study

Reuters
·
Jun 29

Neurosense Rises as Nerve Disease Drug Shows Promise in Study

Reuters
·
Jun 29

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

TIPRANKS
·
Jun 29

Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)

Reuters
·
Jun 29

Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS

THOMSON REUTERS
·
Jun 29

Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months

THOMSON REUTERS
·
Jun 29

Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease

THOMSON REUTERS
·
Jun 25

NeuroSense joins EverythingALS community event on PrimeC data in ALS

Reuters
·
Jun 22

NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000

Reuters
·
Jun 18

Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS

THOMSON REUTERS
·
Jun 11

NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

Reuters
·
Jun 11

Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

TIPRANKS
·
Jun 10

NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042

Reuters
·
Jun 09

NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission

Reuters
·
Jun 08

NeuroSense prices $600,000 private placement at $0.8 per share

Reuters
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

TIPRANKS
·
Apr 27

NeuroSense announces departure of Chief Medical Officer

TIPRANKS
·
Apr 27

NeuroSense CMO Ferenc Tracik steps down, effective April 27

Reuters
·
Apr 24

NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

Reuters
·
Apr 06